Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Brief Commentary
Cardio Oncology with ACOS
Case Report
Case Series
Conference Review
Consensus Statement
Current Issue
Letter to Editor
Media and News
Molecular Insight Story
New Drug Update
Original Article
Position Paper
Response to the letter
Review Article
Short Communication

International Journal of Molecular and Immuno Oncology (IJMIO) is an open-access peer-reviewed journal committed to publishing high-quality articles in the field of Molecular Biological and Immunological aspects of Oncology. The journal is owned by the Alms Tech LLP and published by the Scientific Scholar.

IJMIO is a peer-reviewed 3 (three) issues journal that is published both online and in print jointly by Molecular Oncology Society and Immuno Oncology Leadership Network. It is published by Scientific Scholar. The journal’s full text is available online at ( IJMIO is an Open Access journal, and online access to full text articles is provided at no charge for non-commercial use. The journal does not charge for submission or acceptance of manuscripts.

IJMIO employs the highest standards in publishing, backed by the years of experience of the Molecular Oncology Society and Immuno Oncology Leadership Network. The journal follows stringent peer-review and editorial policies that allow for the selection of high-quality work to be published. All manuscripts are evaluated by peer-review for their quality of science (including novelty, technical methodology, and integrity). The editorial policy is to require all authors to disclose any relevant financial associations and declare that financial interests have not influenced the content of the manuscript being published. This is in keeping with the high ethical standards we strive to ensure for all work published in IJMIO.

Focus and Scope

International Journal of Molecular and Immuno Oncology (IJMIO) is dedicated to providing a platform for highlighting novel and relevant research and exchange of knowledge at the crossroads of bench and bedside research. The goal is to provide information in an understandable format for clinicians and keep up with the fast-paced developments in Molecular Biology and Immunology related to Oncology.


Our audience includes Molecular Oncologists, Immunologists, medical professionals and students.

Review Process

IJMIO has a highly rigorous double-blinded peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts of interest, affiliations and financial disclosures such that the published content is not biased.

In-house submissions that contain the work of any editorial board member, are not allowed to be reviewed by that editorial board member and all decisions regarding this manuscript are made by an independent editor. In addition, these manuscripts are reviewed by the two external reviewers. This is also disclosed in the published manuscript under the section of Conflict of Interest.

Editorial Team

The editorial board comprises a panel of international experts in Molecular and Immuno Oncology from various countries to provide their expertise and guidance to the Editor-In-Chief in maintaining the clarity of content and focus of the journal’s purpose.

About the Editors

Emeritus Editors
Dr. Purvish M. Parikh MD, DNB, FICP, PHD, ECMO, CPI, MBA

Dr. Purvish M. Parikh is

  • Director of Precision Oncology & Research, Asian Cancer Institute
  • Board Member, Maharashtra University of Health Sciences
  • Executive Director, Indian Cooperative Oncology Network
  • Director of Clinical Research and Education, BSES Municipal Hospital
  • Past President, SAARC Federation for Oncologists
  • Past President, Indian Society of Medical & Pediatric Oncology
  • Emeritus Editor, South Asian Journal of Cancer & International Journal of Molecular and Immuno-Oncology.
  • Passionate about Digital Health & Medico-Legal Issues.
  • Unconventional Educator
  • Author of 19 books; 36 chapters in books; 200+ scientific articles

Dr. Randeep Singh MD, DM, ECMO, FCCP

Dr. Singh currently is working as a Senior consultant and unit head at Artemis Hospital, Gurugram. He also owns the ONCOMED clinic at Hauz Khas, Delhi. He has been trained extensively in the management of cancer patients at the prestigious Tata Memorial Hospital (TMH), Mumbai. He did his Doctorate (DM: Medical Oncology) from Tata Memorial Hospital, Mumbai and then worked as a consultant at TMH, Mumbai with the solid tumor-working group before joining the Max group of hospitals. He worked as a Consultant with Max Healthcare for five years. Thereafter he was heading the Department of Medical Oncology at HCG cancer center, Delhi before joining ARTEMIS Hospitals, Gurgaon. His key area of interest is lung cancer, gastrointestinal and breast cancer.

Dr. Singh has more than 40 publications in national and international journals of high impact factor. He has also attended and presented various scientific papers in national and international journals. He is a distinguished faculty at various national and international conferences. He currently serves as Joint Secretary at Indian Society Medical & Pediatric Oncology (ISMPO). He is a co-founder member of the International CME organization and an executive member of various national organizations such as ICON (Indian Co-Operative Oncology Network), ISMPO (Indian Society of Medical & Pediatric Oncology), Delhi Oncology Forum. He is also associated with international societies such as ESMO (European Society of Medical Oncology) & ASCO (American Society of Clinical Oncology).

Facts About the Journal

Scope of the journal
IJMIO is a peer-reviewed journal that highlights the latest developments, approaches, and discoveries in basic, clinical and translational oncology. The journal reviews and accepts original clinical and laboratory-based research manuscripts as well as invited reviews focused on molecular biological and immunological aspects of oncology. Articles addressing contemporary advances and challenges faced in molecular and immune-oncology in developing nations are also strongly encouraged.
Key areas covered by the journal include

  • Biomarkers and individualized therapy
  • Nanotechnology and other technological advances
  • Cancer genetics and epigenetics
  • Cancer microenvironment and cell biology
  • Immunological aspects of tumorigenesis
  • Molecular and immunological therapies
  • Clinical trials

Section Policies
This journal publishes manuscripts in the following sections

  • Original Articles
  • Case Reports
  • Review Articles
  • Educational Forum
  • Editorial
  • New Drug Update
  • Letter to the Editor
  • Short Communication
  • Corrigendum
  • Brief Commentary
  • Consensus Statement
  • Other

All manuscripts submitted through all the sections are peer-reviewed prior to acceptance. It is a peer-reviewed international journal with a double-blind review process. Its frequency of publication is 3 (three) issues per year. The Journal is published both online and in print.


A manuscript published in the journal can be read and downloaded by readers all over the world without any charges or fees. The author retains the copyright of the manuscript and the figures. This allows authors to extend their exposure in the world of medical research and get worldwide recognition for their work.

Abstracting and Indexing Information

The journal is registered with the following abstracting partners:

Google Scholar, ProQuest, ReadCube, CrossRef, Portico

Journal Ethics

International Journal of Molecular and Immuno Oncology is committed to meeting and upholding ethical guidelines at all stages of the publication process. We follow the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE), and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit our Ethical Guidelines Section.

Plagiarism Policy

The journal uses plagiarism check software (iThenticate) on the Editor’s and Reviewer’s panel in the manuscript management system which is used to check and control Plagiarism for each article under a double-blinded peer review process. Any manuscript, that is found to have plagiarism is rejected.

Archival Policy

We use PORTICO for our third-party repository for all articles published with us. All our manuscripts are assigned a DOI number from CROSSREF, and we are members of Crossref

Open Access Publication and Creative Commons Licensing

International Journal of Molecular and Immuno Oncology is an open-access journal, and manuscripts published are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License (CC-BY-NC-SA 4.0), which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Ahead of Print Policy

Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. IJMIO has a policy that changes will not be made after the publication of an article without following accepted procedures for making corrections to the scientific record.

Subscription Information

Copies are provided free to members of the journal’s institution.
For non-members, please log on to


Scientific Scholar LLC ( is a well-respected medical publisher that fully supports open access publishing models, Subscription and Society based journal models through its own in-house peer-review management system – EditorialAssist ( The head office of Scientific Scholar is in Rochester, NY, USA and has a subsidiary arm in India.

The mission of the Scientific Scholar is “Share, Learn and Improve”.